Flerie AB will merge with Toleranzia AB, enhancing its portfolio and market competitiveness in the Life Science sector, with completion anticipated on August 19, 2025.

Information on the Target

Flerie AB (publ) is a proactive and long-term investor within the Life Science sector, boasting a diverse portfolio comprised of innovative companies utilizing groundbreaking technologies. The firm is committed to global investments that support product development and commercial growth, collaborating with other leading investors to tap into hard-to-access private companies. Flerie's active ownership model, extensive networks, and resources aid in accelerating the development of projects within its portfolio, thus creating shareholder value.

Toleranzia AB (publ) is set to undergo a merger with Flerie, with approval granted by the Swedish Companies Registration Office. Following the registration of the merger on August 19, 2025, Toleranzia will be dissolved, and all its assets and liabilities will be transferred to Flerie. Toleranzia’s activities will subsequently be assigned to a newly established subsidiary under Flerie's wholly-owned subsidiary, Flerie Invest AB.

Industry Overview in Sweden

Sweden's Life Science sector is flourishing, supported by a robust ecosystem of innovation and research. The country is home to numerous biotech firms and renowned research institutions, making it